{"title":"Mixed results for esmethadone in Phase 3 depression trial","authors":"","doi":"10.1002/pu.31227","DOIUrl":null,"url":null,"abstract":"<p>A Phase 3 trial of esmethadone as adjunctive treatment for patients with treatment-resistant depression did not meet its primary endpoint of significant improvement in depressive symptoms at 28 days compared with placebo. Esmethadone did show significant improvement over placebo in treatment response rate.</p>","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"35 11","pages":"4"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31227","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
A Phase 3 trial of esmethadone as adjunctive treatment for patients with treatment-resistant depression did not meet its primary endpoint of significant improvement in depressive symptoms at 28 days compared with placebo. Esmethadone did show significant improvement over placebo in treatment response rate.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
